News
8d
Zacks Investment Research on MSNCHMP Issues Positive Opinion for Label Expansion of BMY's OpdivoBristol Myers BMY announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) has recommended approval of Opdivo (nivolumab) for another ...
1d
Zacks Investment Research on MSNVRTX Secures Nod for Expanded Use of CF Drug Kaftrio in EuropeVertex Pharmaceuticals VRTX announced that the European Commission (EC) has expanded the label of its blockbuster cystic ...
Eisai (TYO: 4523) and Biogen (Nasdaq: BIIB) today provided an update on the ongoing regulatory review of the Marketing ...
Accord received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for ...
Bristol Myers Squibb said a key European regulatory committee is backing a formulation of its blockbuster cancer drug Opdivo that can be injected under the skin.
Therapeutics announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a ...
The benefits of naltrexone/bupropion (Mysimba) continue to outweigh its risks, despite ongoing uncertainty about long-term ...
BeiGene (ONC) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion ...
TEVIMBRA is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is ...
Viehbacher, "Biogen") announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has reaffirmed its positive opinion by consensus for the anti ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results